Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.
Sofosbuvir (SOF) with simeprevir (SIM) combination was the first interferon-free regimen that reached optimal results in terms of sustained viral response (SVR). Areas covered: A systematic review of the scientific literature concerning the effects that the SOF/SIM combination had on hepatitis C genotype 1 patients yielded 771 references. After the revision process, four clinical trials and 15 observational studies met the inclusion criteria; in total, these studies involved 5,766 patients. The SVR ranged from 67% to 100% depending on the patients' viral subtype and cirrhosis status. Adverse effects were common, but treatment discontinuation related to drug toxicity occurred in less than 5% of cases. Expert commentary: The SOF/SIM combination exhibits efficacy and tolerability profiles that are similar to those of the other available interferon-free combinations used for non-cirrhotic genotype 1b patients. Meanwhile, for patients with advanced cirrhosis or genotype 1a, this approach cannot be considered a routine treatment option due to the unsatisfactory results.
a Department of Pharmacy , Hospital Universitario Miguel Servet , Zaragoza , Spain.|b Faculty of Pharmacy of the University of Granada , Granada , Spain.
Vicente
V
Gimeno-Ballester
c Department of Digestive Diseases , Hospital Clinico Universitario Lozano Blesa , Zaragoza , Spain.
Miguel Ángel
MÁ
Simón
d Department of Pharmacy , Hospital Royo Villanova , Zaragoza , Spain.
Cristina
C
Trigo
e Clinical Management Service , Hospital Alto Deba , Mondragón , Spain.
Javier
J
Mar
b Faculty of Pharmacy of the University of Granada , Granada , Spain.|f Department of Pharmacy , Complejo Hospitalario de Navarra , Pamplona , Spain.
Ramón
R
San Miguel
D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D018579:Patient Selection; D012307:Risk Factors; D000069616:Simeprevir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000069616:Simeprevir; D000069474:Sofosbuvir
Chronic hepatitis C; direct acting antivirals; genotype 1; pegylated interferon; protease inhibitors; ribavirin; simeprevir; sofosbuvir; systematic review